Rigel Reports Q2 2026 Financial Results and In-Licenses VEPPELLEC
Rigel Pharmaceuticals reported $78.7 million in Q2 2026 revenues and $17.3 million in net income. The company advanced its commercial portfolio by in-licensing the PROTAC vepdegestrant from Arvinas.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day